CA3056090A1 - Methods and compositions for inducing immune responses against clostridium difficile - Google Patents
Methods and compositions for inducing immune responses against clostridium difficile Download PDFInfo
- Publication number
- CA3056090A1 CA3056090A1 CA3056090A CA3056090A CA3056090A1 CA 3056090 A1 CA3056090 A1 CA 3056090A1 CA 3056090 A CA3056090 A CA 3056090A CA 3056090 A CA3056090 A CA 3056090A CA 3056090 A1 CA3056090 A1 CA 3056090A1
- Authority
- CA
- Canada
- Prior art keywords
- toxin
- protein
- amino acid
- polypeptide
- multivalent immunogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/116—Polyvalent bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471636P | 2017-03-15 | 2017-03-15 | |
| US62/471,636 | 2017-03-15 | ||
| US201762474434P | 2017-03-21 | 2017-03-21 | |
| US62/474,434 | 2017-03-21 | ||
| PCT/US2018/022597 WO2018170238A2 (en) | 2017-03-15 | 2018-03-15 | Methods and compositions for inducing immune responses against clostridium difficile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3056090A1 true CA3056090A1 (en) | 2018-09-20 |
Family
ID=63523217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3056090A Pending CA3056090A1 (en) | 2017-03-15 | 2018-03-15 | Methods and compositions for inducing immune responses against clostridium difficile |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11123419B2 (https=) |
| EP (1) | EP3595709A4 (https=) |
| JP (2) | JP7149285B2 (https=) |
| KR (1) | KR102640722B1 (https=) |
| CN (1) | CN110691609B (https=) |
| AU (1) | AU2018236352B2 (https=) |
| BR (1) | BR112019019117A2 (https=) |
| CA (1) | CA3056090A1 (https=) |
| IL (1) | IL269258B2 (https=) |
| MX (1) | MX2019010948A (https=) |
| SG (1) | SG11201908376UA (https=) |
| WO (1) | WO2018170238A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI815599B (zh) | 2011-04-22 | 2023-09-11 | 美商惠氏有限責任公司 | 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法 |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| MX2019010948A (es) * | 2017-03-15 | 2020-01-09 | Novavax Inc | Métodos y composiciones para inducir respuestas inmunitarias contra clostridium difficile. |
| WO2021255690A2 (en) * | 2020-06-19 | 2021-12-23 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
| WO2023232901A1 (en) | 2022-06-01 | 2023-12-07 | Valneva Austria Gmbh | Clostridium difficile vaccine |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| WO1999011711A1 (en) * | 1997-09-04 | 1999-03-11 | Eastman Chemical Company | Thermoplastic polyurethane additives for enhancing solid state polymerization rates |
| CA2733425A1 (en) | 2008-08-06 | 2010-02-11 | Emergent Product Development Uk Limited | Vaccines against clostridium difficile and methods of use |
| US10046040B2 (en) * | 2009-11-16 | 2018-08-14 | University Of Maryland, Baltimore | Multivalent live vector vaccine against Clostridium difficile-associated disease |
| US20130039973A1 (en) * | 2011-08-03 | 2013-02-14 | Henry J. Smith | Viral Immunogenic Compositions |
| RU2014117068A (ru) | 2011-09-30 | 2015-11-10 | Новавакс, Инк. | Вакцина на основе рекомбинантных наночастиц f из rsv против респираторно-синцитиального вируса |
| AR089797A1 (es) * | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| WO2014086787A1 (en) | 2012-12-05 | 2014-06-12 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| GB201223342D0 (en) * | 2012-12-23 | 2013-02-06 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| CN105451762A (zh) | 2013-04-22 | 2016-03-30 | 俄克拉荷马州大学评议会 | 艰难梭菌疫苗及使用方法 |
| WO2015063647A1 (en) * | 2013-11-01 | 2015-05-07 | Pfizer Inc. | Vectors for expression of prostate-associated antigens |
| BE1022949B1 (fr) * | 2014-06-25 | 2016-10-21 | Glaxosmithkline Biologicals S.A. | Composition immunogene |
| CN106220737B (zh) * | 2016-07-21 | 2020-11-10 | 中国人民解放军军事医学科学院微生物流行病研究所 | 融合蛋白及其在治疗艰难梭菌相关疾病中的应用 |
| MX2019010948A (es) | 2017-03-15 | 2020-01-09 | Novavax Inc | Métodos y composiciones para inducir respuestas inmunitarias contra clostridium difficile. |
-
2018
- 2018-03-15 MX MX2019010948A patent/MX2019010948A/es unknown
- 2018-03-15 CA CA3056090A patent/CA3056090A1/en active Pending
- 2018-03-15 KR KR1020197030108A patent/KR102640722B1/ko active Active
- 2018-03-15 WO PCT/US2018/022597 patent/WO2018170238A2/en not_active Ceased
- 2018-03-15 CN CN201880025192.8A patent/CN110691609B/zh active Active
- 2018-03-15 US US16/494,517 patent/US11123419B2/en active Active
- 2018-03-15 SG SG11201908376U patent/SG11201908376UA/en unknown
- 2018-03-15 EP EP18767173.0A patent/EP3595709A4/en active Pending
- 2018-03-15 JP JP2019550687A patent/JP7149285B2/ja active Active
- 2018-03-15 IL IL269258A patent/IL269258B2/en unknown
- 2018-03-15 AU AU2018236352A patent/AU2018236352B2/en active Active
- 2018-03-15 BR BR112019019117A patent/BR112019019117A2/pt unknown
-
2021
- 2021-08-10 US US17/398,610 patent/US11938179B2/en active Active
-
2022
- 2022-09-26 JP JP2022153071A patent/JP7397145B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190125470A (ko) | 2019-11-06 |
| RU2019132111A3 (https=) | 2021-06-29 |
| EP3595709A2 (en) | 2020-01-22 |
| SG11201908376UA (en) | 2019-10-30 |
| KR102640722B1 (ko) | 2024-02-26 |
| US11938179B2 (en) | 2024-03-26 |
| JP2020509770A (ja) | 2020-04-02 |
| WO2018170238A3 (en) | 2018-10-18 |
| IL269258B2 (en) | 2023-09-01 |
| US11123419B2 (en) | 2021-09-21 |
| US20200085934A1 (en) | 2020-03-19 |
| BR112019019117A2 (pt) | 2020-05-05 |
| AU2018236352A1 (en) | 2019-10-03 |
| JP2022179543A (ja) | 2022-12-02 |
| JP7397145B2 (ja) | 2023-12-12 |
| RU2019132111A (ru) | 2021-04-15 |
| CN110691609B (zh) | 2024-04-19 |
| EP3595709A4 (en) | 2020-12-23 |
| MX2019010948A (es) | 2020-01-09 |
| US20220211834A1 (en) | 2022-07-07 |
| IL269258B1 (en) | 2023-05-01 |
| JP7149285B2 (ja) | 2022-10-06 |
| CN110691609A (zh) | 2020-01-14 |
| WO2018170238A2 (en) | 2018-09-20 |
| AU2018236352B2 (en) | 2024-04-04 |
| IL269258A (en) | 2019-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11938179B2 (en) | Methods and compositions for inducing immune responses against Clostridium difficile | |
| CN103154242B (zh) | 诺如病毒衍生的免疫原性组合物和方法 | |
| US20080008725A1 (en) | Influenza recombinant subunit vaccine | |
| WO2017041100A2 (en) | Vaccine compositions having improved stability and immunogenicity | |
| US20170354729A1 (en) | Vaccine compositions containing modified zika virus antigens | |
| EP2061887B1 (en) | Vlp based influenza vaccine delivery system | |
| JP2013520487A (ja) | 免疫原性タンパク質および組成物 | |
| JP2012532626A (ja) | 無毒化されたＥｓｃｈｅｒｉｃｈｉａｃｏｌｉ免疫原 | |
| RU2781057C2 (ru) | Способы и композиции для индукции иммунного ответа против clostridium difficile | |
| RU2781057C9 (ru) | Способы и композиции для индукции иммунного ответа против clostridium difficile | |
| US9493518B2 (en) | Compositions and methods for treating clostridium difficile-associated diseases | |
| AU2020229815B2 (en) | Methods for preventing disease or disorder caused by RSV infection | |
| US20240335523A1 (en) | Glycoengineered Foldon Domains and Related Compositions and Methods | |
| HK40075643A (en) | Vaccine compositions with improved stability and immunogenicity | |
| HK40075644A (en) | Vaccine compositions with improved stability and immunogenicity | |
| HK1139597A (en) | Influenza recombinant subunit vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220926 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241204 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D138 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INTERVIEW PERFORMED Effective date: 20250114 Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D136 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INTERVIEW REQUEST AUTHORIZED Effective date: 20250114 Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D135 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INTERVIEW REQUEST RECEIVED Effective date: 20250114 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250307 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250307 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250307 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250403 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250407 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250408 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250408 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D138 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INTERVIEW PERFORMED Effective date: 20250425 Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D136 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INTERVIEW REQUEST AUTHORIZED Effective date: 20250425 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250430 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250829 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251220 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251220 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251220 |